Wall Street analyst estimates for BioRestorative Therapies, Inc. (BRTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 0.76 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36355 | $81000 | $111000 | $130000 | $77000 | $46000 | $119800 | $145800 | $401000 | $359700 |
| Cost of Revenue | $102 | $259260 | 0 | 0 | 0 | 0 | 0 | 0 | $28072 | $23844 |
| Gross Profit | $36253 | -$178260 | $111000 | $130000 | $77000 | $46000 | $119800 | $145800 | $372928 | $335856 |
| Research & Development | $2.9M | $2.2M | $1.5M | $1.7M | $876829 | $729058 | $3.5M | $4.0M | $5.3M | $10.1M |
| Selling, General & Admin | $4.9M | $6.3M | $6.2M | $6.8M | $2.0M | $25.6M | $15.6M | $11.3M | $6.6M | $5.9M |
| Operating Expenses | $7.8M | $8.5M | $7.8M | $8.6M | $2.8M | $26.4M | $19.0M | $15.4M | $11.9M | $16.0M |
| Operating Income | -$7.8M | -$8.4M | -$7.6M | -$8.4M | -$2.8M | -$26.3M | -$18.9M | -$15.2M | -$11.6M | -$15.6M |
| EBITDA | -$7.6M | -$8.1M | -$9.1M | -$9.3M | -$9.5M | -$42.4M | -$13.1M | -$15.0M | -$8.8M | -$14.0M |
| Interest Expense | $763944 | $1.1M | $3.2M | $5.1M | $1.6M | $1.8M | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$8.6M | -$9.4M | -$12.5M | -$14.6M | -$11.3M | -$44.3M | -$13.2M | -$10.4M | -$9.0M | -$14.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$8.6M | -$9.4M | -$12.5M | -$14.6M | -$11.3M | -$44.3M | -$13.2M | -$10.4M | -$9.0M | -$14.2M |
| EPS | $-168000.00 | $-139200.00 | $-131246.40 | $-52601.60 | $-571.20 | $-746.00 | $-73.00 | $-49.40 | $-23.20 | $-31.60 |
| EPS (Diluted) | $-168000.00 | $-139200.00 | $-131246.40 | $-52601.60 | $-571.20 | $-746.00 | $-73.00 | $-49.40 | $-23.20 | $-31.60 |
| Shares Outstanding (Diluted) | $51 | $68 | $95 | $278 | $19735 | $59387 | $180893 | $210917 | $388197 | $449656 |
Price
| Price | $2.55 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BOLT · COCP · DWTX · EDSA · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of BRTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks